Expertise in

conditions

Kazuhisa H. Takahashi

Tokyo, JP

Expertise in

conditions

Tokyo, JP

Overview

Kazuhisa Takahashi practices practicing medicine in Tokyo, Japan.

Takahashi is highly rated in 58 conditions, according to our data. Their clinical expertise encompasses Lymphangioleiomyomatosis, Lung Cancer, Birt-Hogg-Dube Syndrome, Spinal Fusion, and Osteotomy.

They are actively involved in clinical research, co-authoring 836 peer reviewed articles and participating in 1 clinical trial.

Locations

Tokyo, Japan

Other Locations

Osaka, 5731010, Japan

Bunkyo, Japan

Ohashi, Japan

Hirakata, Japan

Hongo, 1138421, Japan

Kashiwa, Japan

Yokohama, Japan

Kitano, Japan

Japan

Okazaki, Japan

Kyoto, Japan

Tottori, Japan

Nankoku, 7838509, Japan

Itabashi, 1740051, Japan

Chiba, Japan

Hirosaki, Japan

Anjo, Japan

Nagaoka, 9402188, Japan

Kawasaki, 2120013, Japan

Chuo, 2600856, Japan

Chuo, 2608670, Japan

Nagoya, Japan

Koshigaya, Japan

Nagasaki, Japan

Koshi, Japan

Suita, 5650871, Japan

Niigata, Japan

Asahi, 5458585, Japan

Sugimoto, 5588585, Japan

Otsu, Japan

Izunokuni, 4102295, Japan

Shimonagakubo, 4118777, Japan

Sagamihara, Japan

Kanagawa, Japan

Hiroshima, Japan

Matsudo, Japan

Meguro, 1538902, Japan

Tochigi, Japan

Okayama, Japan

Murakami, 2608670, Japan

Nigata-honmachi, Japan

Senboku, Japan

Maizuru Fisheries Research Station, Nagahama, Maizuru, 6250086, Japan

Shimotsuke, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC

Enrollment Status: Active_not_recruiting

Publish Date: March 04, 2026

Intervention Type: Drug

Study Drug: Selpercatinib

Study Phase: Phase 3

836 Total Publications

Study of weight loss intervention to find an effective strategy for obesity management and the TARGET of weight loss amount for reducing health disorders (SLIM-TARGET): a randomized controlled trial.

Journal: Endocrine journal

Published: September 02, 2026

View All 836 Publications

Frequently Asked Questions about Kazuhisa H. Takahashi

Is Kazuhisa H. Takahashi a top-rated expert for Lymphangioleiomyomatosis?

MediFind is an objective health platform that identifies experts based on real-world data. Kazuhisa H. Takahashi is classified as an Elite expert for Lymphangioleiomyomatosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Kazuhisa H. Takahashi participate in research or clinical trials?

Yes. Kazuhisa H. Takahashi has published 836 articles and abstracts on conditions like Lymphangioleiomyomatosis. You can view a list of Kazuhisa H. Takahashi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Takahashi's expertise for a condition

ConditionClose